Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cellsAdam J. Lamble, Nirali N. Shah, Seth M. Steinberg et al.|Blood Advances|2022Cited by 149
Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapyEmily M. Hsieh, Regina M. Myers, Bonnie Yates et al.|Blood Advances|2022Cited by 34
Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free SurvivalAgne Taraseviciute, Nirali N. Shah, Seth M. Steinberg et al.|Blood|2020Cited by 24